Immuneering (IMRX) Competitors $2.00 +0.16 (+8.70%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IMRX vs. BMEA, INBX, XBIT, CRDF, CMPX, LFVN, SLN, MGNX, CADL, and CYBNShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Biomea Fusion (BMEA), Inhibrx (INBX), XBiotech (XBIT), Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), LifeVantage (LFVN), Silence Therapeutics (SLN), MacroGenics (MGNX), Candel Therapeutics (CADL), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Biomea Fusion Inhibrx XBiotech Cardiff Oncology Compass Therapeutics LifeVantage Silence Therapeutics MacroGenics Candel Therapeutics Cybin Biomea Fusion (NASDAQ:BMEA) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Which has stronger valuation & earnings, BMEA or IMRX? Immuneering has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.05Immuneering$320K194.06-$53.47M-$1.97-1.02 Does the MarketBeat Community believe in BMEA or IMRX? Biomea Fusion received 27 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 68.29% of users gave Biomea Fusion an outperform vote while only 64.44% of users gave Immuneering an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5668.29% Underperform Votes2631.71% ImmuneeringOutperform Votes2964.44% Underperform Votes1635.56% Does the media favor BMEA or IMRX? In the previous week, Biomea Fusion had 10 more articles in the media than Immuneering. MarketBeat recorded 15 mentions for Biomea Fusion and 5 mentions for Immuneering. Biomea Fusion's average media sentiment score of 0.45 beat Immuneering's score of -0.17 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BMEA or IMRX more profitable? Immuneering's return on equity of -79.19% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Immuneering N/A -79.19%-69.08% Do analysts prefer BMEA or IMRX? Biomea Fusion currently has a consensus target price of $39.36, suggesting a potential upside of 830.58%. Immuneering has a consensus target price of $12.80, suggesting a potential upside of 540.00%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities analysts clearly believe Biomea Fusion is more favorable than Immuneering.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Immuneering 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders & institutionals have more ownership in BMEA or IMRX? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by insiders. Comparatively, 25.0% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, BMEA or IMRX? Biomea Fusion has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. SummaryBiomea Fusion beats Immuneering on 10 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.10M$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-1.0210.5591.0817.15Price / Sales194.06195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book0.655.104.784.78Net Income-$53.47M$151.51M$119.77M$225.60M7 Day Performance22.32%-2.12%-1.87%-1.23%1 Month Performance-5.21%-3.11%11.46%3.07%1 Year Performance-71.35%11.52%30.53%16.48% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.2169 of 5 stars$2.00+8.7%$12.80+540.0%-70.1%$62.10M$320,000.00-1.0260News CoverageBMEABiomea Fusion3.8965 of 5 stars$5.89+4.4%$39.36+568.3%-69.2%$213.45MN/A-1.4150Analyst ForecastINBXInhibrx1.494 of 5 stars$14.58-0.3%N/A-49.7%$211.06M$1.57M0.00166XBITXBiotechN/A$6.92-0.4%N/A+61.9%$210.94M$4.01M-6.41100CRDFCardiff Oncology2.0266 of 5 stars$4.07+3.8%$10.33+153.9%+195.8%$208.10M$490,000.00-4.1720CMPXCompass Therapeutics2.6637 of 5 stars$1.49+2.1%$6.75+353.0%-13.2%$205.01M$850,000.00-4.0720LFVNLifeVantage4.5453 of 5 stars$16.33+1.8%N/A+178.9%$204.53M$196.01M50.13260Analyst ForecastNews CoveragePositive NewsSLNSilence Therapeutics3.4352 of 5 stars$6.81+5.6%$57.20+739.9%-59.0%$203.82M$31.55M-4.11100MGNXMacroGenics3.5243 of 5 stars$3.21+0.3%$7.63+137.5%-67.7%$201.47M$139.77M-2.03430CADLCandel Therapeutics2.7535 of 5 stars$6.13-9.2%$11.00+79.4%+681.3%$199.08M$120,000.00-3.6060Analyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumeCYBNCybin1.5606 of 5 stars$9.80+0.2%$138.00+1,308.2%N/A$195.92MN/A-1.4850 Related Companies and Tools Related Companies BMEA Alternatives INBX Alternatives XBIT Alternatives CRDF Alternatives CMPX Alternatives LFVN Alternatives SLN Alternatives MGNX Alternatives CADL Alternatives CYBN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts